90
Participants
Start Date
October 17, 2022
Primary Completion Date
February 26, 2027
Study Completion Date
February 26, 2027
Cevostamab
Cevostamab will be administered by IV infusion in 21-day cycles.
Tocilizumab
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Calvary Mater Newcastle, Waratah
UZ Leuven Gasthuisberg, Leuven
St Vincent's Hospital Melbourne, Fitzroy
Icahn School of Medicine at Mount Sinai (ISMMS), New York
Memorial Sloan Kettering Cancer Center, New York
A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette, Turin
Fond. IRCCS Istituto Nazionale Tumori, Milan
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg
University of Maryland Greenebaum Cancer Center, Baltimore
Asst Papa Giovanni Xxiii, Bergamo
Hospital Univ. 12 de Octubre, Madrid
Mayo Clinic-Jacksonville, Jacksonville
Tennessee Oncology - Nashville, Nashville
Policlinico S.Orsola-Malpighi, Bologna
CHU NANTES - Hôtel Dieu, Nantes
Klinik der Uni zu Köln, Cologne
Mayo Clinic - Rochester, Rochester
APHP - Hospital Saint Louis, Paris
Hunstman Cancer Institute, Salt Lake City
CHU de Poitiers - La Miletrie, Poitiers
Universitätsklinikum Würzburg, Würzburg
Sheba Medical Center, Ramat Gan
Sourasky Medical Centre, Tel Aviv
Hadassah Ein Karem Hospital, Jerusalem
University of Colorado, Aurora
Dana Farber Cancer Institute, Boston
Hospital Clínic i Provincial, Barcelona
Hoffmann-La Roche
INDUSTRY